Stock Analiz

Foghorn Therapeutics Inc. FHTX

Biotechnology: Pharmaceutical Preparations · IPO 2020 · data as of November 13, 2026

$2.07Market cap $124M
Open the interactive analysis →

Foghorn Therapeutics Inc. (FHTX) is a healthcare company listed in the US with a market value of about $124M. In the twelve months to September 30, 2026 it had revenue of $112M and net income of $9M, a net margin of 8.4%.

Its overall Stock Analiz score is 1.8 out of 5 (weak). The strongest part is future growth (4/5); the weakest is shareholder returns (0/5).

Key numbers: a P/E of 16.0, 5-year revenue growth of 135% a year, a 5-year average ROIC of -139%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 95% below the current price.

About Foghorn Therapeutics

Foghorn Therapeutics is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2020. Revenue went from $430000 in 2020 to $31M in 2025, growth of about 135.1% a year. It was profitable in 0 of the last 7 years in our data. Its share count rose by 51% over three years (dilution for shareholders). It spends 277% of revenue on research and development.

Score: 1.8 / 5

Value2/5
Future growth4/5
Track record2/5
Financial health1/5
Shareholder returns0/5

Checks passed

  • P/E below 25
  • P/E below the industry median
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • 5-year revenue growth above 8% a year
  • ROE above 15%

Checks not passed

  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year
  • 5-year average ROIC above 12%
  • Profitable 5 years in a row
  • Positive free cash flow

Valuation

P/E (TTM)16.0
Forward P/E—
P/FCF—
P/S1.1
P/B—
EV/EBITDA22.3
PEG—
Dividend yield0.00%
FCF yield-67.4%
Shareholder yield0.0%
Intrinsic value vs. price−95%

Growth and quality

Revenue growth (1 yr)36.8%
Revenue growth (5 yrs, per year)135.1%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-1831.9%
ROIC (5-yr avg.)-139.1%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 7 years

Fiscal yearTTM2025202420232022202120202019
Revenue$112M$31M$23M$34M$19M$1M$430000—
Net income$9M-$74M-$87M-$98M-$109M-$101M-$69M-$51M
Free cash flow-$84M-$86M-$101M-$119M$192M-$54M-$47M-$47M
EPS (diluted)$0.13$-1.18$-1.58$-2.34$-2.62$-2.73$-6.23$-12.20
Net margin8.4%-240.3%-383.2%-288.2%-566.3%-7681.6%-16000.0%—
ROIC————-226.9%-51.3%-23.7%—

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

What is Foghorn Therapeutics’s P/E ratio?

About 16.0, based on the last twelve months of diluted earnings per share.

Is Foghorn Therapeutics stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 95% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Foghorn Therapeutics pay a dividend?

Not currently.

Is Foghorn Therapeutics a good stock to buy?

We do not give buy or sell advice. Foghorn Therapeutics scores 1.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.